顺铂等药物灌注化疗和恩度治疗恶性胸腹腔积液的研究

Clinical research of Endostar combined with Derfusion chemotherapy on malignant pleural and ascites

目的观察顺铂等灌注和恩度治疗恶性胸腹积液的临床疗效及安全性。方法 62例晚期恶性胸腹水患者,治疗组32例,胸/腹腔内灌注恩度和化疗药物DDP/5-FU,对照组30例,仅灌注化疗药物DDP/5-FU,均3次/周,连续4周为一疗程,休息4周后,评价疗效及不良反应。结果治疗组中12例CR,16例PR,3例SD,1例PD,有效率为87.5%;对照组6例CR,13例PR,7例SD,4例PD,有效率为63.3%,两组比较差异有统计学意义(P<0.05),不良反应发生率两组比较无统计学意义(P>0.05)。结论顺铂等加恩度灌注治疗恶性胸腹腔积液有较好的疗效和安全性,并有效提高了晚期肿瘤患者的生活质量,值得临床进一步推广应用。

Objective To observe clinical efficacy and safety of cisplatin perfusion and Endostar in the treatment of malignant pleural effusion.Methods Totally 62 cases of patients with malignant pleural and ascites：32 in the treatment group,who were perfused endostar combined with chemotherapy DDP or 5-FU;30 in the control group,who only perfused chemotherapy DDP or 5-FU.The treatment was three times a week.4 weeks was a cycle,then evaluate the efficacy and adverse reactions.Results The effective rate of the two groups was 87.5%,63.3%,the difference was statistically significant（P0.05）,the incidence of adverse reactions between the two groups was not statistically significant（P0.05）.Conclusion Endostar combined with derfusion chemotherapy on malignant pleural and ascites has better efficacy and higher safety,and improves the quality of life for malignant tumor patients.It is worth further clinical application.